Neuro-Oncology News

Patients with advanced cancer who arrived at the ED with delirium had increased rates of hospitalization and ICU admissions, as well as shorter survival rates, according to a study published in The Oncologist.

Patients with advanced cancer had significantly lower survival rates following in-hospital cardiac arrest than those without advanced cancer, according to a retrospective study published in Journal of Oncology Practice.

Four leading national cancer organizations have united in their mission to reduce the number of health disparities in the United States and to ensure all patients, regardless of social demographics and socioeconomic status, benefit from cancer research, according to a joint position statement published in Journal of Clinical Oncology.

NCI and the Children’s Oncology Group today announced enrollment opened for a phase 2 study designed to evaluate targeted therapies in children and adolescents with solid tumors.

Senator John McCain (R-AZ) may choose from a variety of treatment options following the removal of a glioblastoma associated with a blood clot above his left eye.

ASCO today issued a position statement that proposes a wide range of cost-cutting strategies that can be tested to help lower drug costs based on a standard definition of value.

The FDA has taken several actions in the past week related to oncology treatments.

An FDA advisory committee today expressed unanimous support of ABP 215, a biosimilar candidate to bevacizumab.

The FDA granted orphan drug designation to entrectinib for the treatment of patients with NTRK fusion–positive solid tumors, according to the drug’s manufacturer.

Holocaust survivors exposed to a variety of severe deprivations demonstrated a small, but consistent, increase in cancer risk, according to results of a nationwide cohort study conducted in Israel.